• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

zeste 同源物2增强子(EZH2)通过对肾细胞癌中E-钙黏蛋白的表观遗传抑制促进肿瘤细胞迁移和侵袭。

Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.

作者信息

Liu Li, Xu Zhibing, Zhong Lei, Wang Hang, Jiang Shuai, Long Qilai, Xu Jiejie, Guo Jianming

机构信息

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.

出版信息

BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702. Epub 2015 Apr 21.

DOI:10.1111/bju.12702
PMID:24612432
Abstract

OBJECTIVE

To investigate the molecular mechanism and clinical significance for an oncogenic role of enhancer of zeste homolog 2 (EZH2) in renal cell carcinoma (RCC).

MATERIALS AND METHODS

Immunohistochemistry analyses of EZH2, histone H3 trimethyl Lys27 (H3K27me3) and E-cadherin were performed in tumour tissue samples from 257 patients with RCC. Regulatory effects of EZH2 on E-cadherin expression were examined by quantitative real-time polymerase chain reaction, Western blot, chromatin immunoprecipitation assay and immunohistochemical staining. Migration and invasion assays were performed in RCC cell lines. Tumour xenograft experiments with RCC cells were carried out in nude mice.

RESULTS

EZH2 promoted migration and invasion in RCC cell lines. Silencing EZH2 with short-hairpin EZH2 (shEZH2) or 3-deazaneplanocin A (DZNep) inhibited migration and invasion (P < 0.001), up-regulated the expression of E-cadherin in vitro, inhibited tumour growth, and prolonged survival in vivo (P = 0.022). EZH2 expression accompanied with E-cadherin repression was associated with advanced disease stage (P = 0.004) and poor overall (P < 0.001) and disease-free survival (P < 0.001).

CONCLUSION

EZH2 may contribute to RCC progression and is a potential therapeutic target for advanced RCC.

摘要

目的

探讨zeste同源物2增强子(EZH2)在肾细胞癌(RCC)中致癌作用的分子机制及临床意义。

材料与方法

对257例RCC患者的肿瘤组织样本进行EZH2、组蛋白H3三甲基赖氨酸27(H3K27me3)和E-钙黏蛋白的免疫组织化学分析。通过定量实时聚合酶链反应、蛋白质免疫印迹法、染色质免疫沉淀试验和免疫组织化学染色检测EZH2对E-钙黏蛋白表达的调控作用。在RCC细胞系中进行迁移和侵袭试验。在裸鼠中进行RCC细胞的肿瘤异种移植实验。

结果

EZH2促进RCC细胞系的迁移和侵袭。用短发夹EZH2(shEZH2)或3-去氮杂氮胞苷(DZNep)沉默EZH2可抑制迁移和侵袭(P < 0.001),在体外上调E-钙黏蛋白的表达,抑制肿瘤生长,并延长体内生存期(P = 0.022)。EZH2表达伴E-钙黏蛋白抑制与疾病晚期(P = 0.004)、总体预后差(P < 0.001)和无病生存期短(P < 0.001)相关。

结论

EZH2可能促进RCC进展,是晚期RCC的潜在治疗靶点。

相似文献

1
Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.zeste 同源物2增强子(EZH2)通过对肾细胞癌中E-钙黏蛋白的表观遗传抑制促进肿瘤细胞迁移和侵袭。
BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702. Epub 2015 Apr 21.
2
Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.锌指增强子同源物2、基质金属蛋白酶-2和金属蛋白酶组织抑制剂-2表达的改变与肾细胞癌的体内外骨转移相关。
Mol Med Rep. 2015 May;11(5):3585-92. doi: 10.3892/mmr.2015.3164. Epub 2015 Jan 8.
3
Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.EZH2 表达与透明细胞肾细胞癌的转移和不良临床结局相关:一项比较研究和文献复习。
Arch Pathol Lab Med. 2013 Oct;137(10):1326-36. doi: 10.5858/arpa.2012-0525-OA.
4
MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.微小RNA-26a通过抑制zeste同源物2增强子来抑制人肝细胞癌中的上皮-间质转化。
J Hematol Oncol. 2016 Jan 6;9:1. doi: 10.1186/s13045-015-0229-y.
5
EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.EZH2通过H3K27me3介导上皮-间质转化促进喉鳞状细胞癌的侵袭和转移。
Biochem Biophys Res Commun. 2016 Oct 14;479(2):253-259. doi: 10.1016/j.bbrc.2016.09.055. Epub 2016 Sep 13.
6
The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.多梳蛋白zeste 2增强子是宫颈癌的一个新的治疗靶点。
Clin Exp Pharmacol Physiol. 2015 May;42(5):458-64. doi: 10.1111/1440-1681.12382.
7
EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.EZH2 通过与 HDAC1/HDAC2 和 Snail 形成共抑制复合物来抑制 E-钙黏蛋白,从而支持鼻咽癌细胞的侵袭能力。
Oncogene. 2012 Feb 2;31(5):583-94. doi: 10.1038/onc.2011.254. Epub 2011 Jun 20.
8
Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.YB1和EZH2的过表达与肾细胞癌的癌症转移及不良预后相关。
Tumour Biol. 2015 Sep;36(9):7159-66. doi: 10.1007/s13277-015-3417-z. Epub 2015 Apr 17.
9
Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.抑制增强子的外显子 2 (EZH2)的表达与子宫内膜癌细胞系中的肿瘤细胞增殖、迁移和侵袭减少有关。
Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. doi: 10.1097/IGC.0b013e318296a265.
10
HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.HOX 转录反义基因间 RNA 通过与胃癌中的 EZH2 结合来抑制 E-钙黏蛋白的表达。
World J Gastroenterol. 2017 Sep 7;23(33):6100-6110. doi: 10.3748/wjg.v23.i33.6100.

引用本文的文献

1
Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas.基于免疫及新型疗法在变异型组织学肾细胞癌中的应用
Cancers (Basel). 2025 Jan 20;17(2):326. doi: 10.3390/cancers17020326.
2
Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome.评估 EZH2 抑制在毛细支气管炎闭塞综合征小鼠模型中的治疗潜力。
Transpl Int. 2024 Oct 25;37:13227. doi: 10.3389/ti.2024.13227. eCollection 2024.
3
Ailanthone suppresses cell proliferation of renal cell carcinoma partially via inhibition of EZH2.
臭椿酮通过部分抑制EZH2来抑制肾细胞癌的细胞增殖。
Discov Oncol. 2024 Sep 19;15(1):464. doi: 10.1007/s12672-024-01347-9.
4
EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4.EZH2 通过 E2F1、GLI1、CDK3 和 Mcm4 调控胰腺癌细胞。
Hereditas. 2023 May 17;160(1):23. doi: 10.1186/s41065-023-00280-1.
5
The role of histone methylation in renal cell cancer: an update.组蛋白甲基化在肾细胞癌中的作用:最新进展
Mol Biol Rep. 2023 Mar;50(3):2735-2742. doi: 10.1007/s11033-022-08124-3. Epub 2022 Dec 28.
6
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.透明细胞肾细胞癌中酪氨酸激酶抑制剂耐药的分子机制。
Int J Urol. 2022 Dec;29(12):1419-1428. doi: 10.1111/iju.15042. Epub 2022 Sep 19.
7
DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma.DMDRMR 通过拮抗 DAB2IP 促进透明细胞肾细胞癌的血管生成。
Cell Death Dis. 2022 May 13;13(5):456. doi: 10.1038/s41419-022-04898-3.
8
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌对免疫治疗和抗血管生成治疗耐药的分子机制
Cancers (Basel). 2021 Nov 28;13(23):5981. doi: 10.3390/cancers13235981.
9
The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials.组蛋白赖氨酸 N-甲基转移酶在胶质瘤微环境中的关键免疫调节和抗炎作用:其生物标志物和治疗潜力。
Anal Cell Pathol (Amst). 2021 Oct 27;2021:4907167. doi: 10.1155/2021/4907167. eCollection 2021.
10
Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas.在软骨肉瘤中,先使用表观遗传药物3-去氮杂氮胞苷(DZNep)预处理,然后与顺铂联合治疗可增强对铂类疗法的反应。
Cancers (Basel). 2021 Sep 16;13(18):4648. doi: 10.3390/cancers13184648.